Gamma Biosciences has agreed to make a controlling investment in Mirus Bio for nucleic acid delivery based in Madison, Wisconsin. The transaction will support Mirus’ plans to expand good manufacturing practice (GMP) production and commercialisation of its flagship product TransIT VirusGEN for large scale manufacturing of AAV and LV-based viral vectors for gene therapy, as well as further development and commercialisation of the platform for in vivo delivery applications.
Originally developed for therapeutic delivery of RNA, Mirus LPNCs have been adapted for a wide range of gene delivery applications. Demand for efficient and scalable gene delivery technologies continues to increase as larger volumes of viral vector are required to support the growing number of gene therapies in development. TransIT VirusGen and Mirus’ portfolio of additional products and services enable customers at both research and clinical scales achieve cost effective, industry leading functional titres.
“Highly efficient, GMP compliant nucleic acid delivery into a wide variety of cell types will continue to be a critical path item for advanced therapies, from viral vectors such as AAV for gene therapy to engineered cellular therapies to novel mRNA based vaccines,” said Matt Gunnison, President of Gamma Biosciences. “Mirus brings decades of experience in transfection and cell engineering and a portfolio of best-in-class transfection products for in vitro and in vivo delivery, adding a new foundational platform that complements Gamma’s existing offering in advanced therapy manufacturing.”
“Delivery of biomolecules into cells is a mainstay of Mirus’ impact on biology research. Doing this efficiently, across a broad range of cells, while maximising cell viability and recovery is what Mirus Bio has excelled at for more than 25 years,” said Jim Hagstrom, PhD, President and Co-founder of Mirus Bio. “We are proud to join forces with Gamma Biosciences and KKR to build a leading player in next-generation bioprocessing, and we are excited to leverage their strong expertise in biomanufacturing as well as their global network in cell and gene therapy. Together, we are very well positioned to realise Mirus’ vision of commercialising our scalable cGMP platforms for clinical use with the launch of TransIT VirusGEN GMP, while maintaining our commitment to basic scientific researchers around the world.”
Image credit: CDC
